CellVec is honoured to be named a winner in the Best Biologics CMO in South East Asia category at the Asia-Pacific Biologics CMO Excellence Awards 2022!   This contributes to our upward trajectory as we work to ensure that as cancer treatments improve, more patients benefit....

CellVec is honoured to be named a winner in the Best Biologics CMO in South East Asia category at the Asia-Pacific Biologics CMO Excellence Awards 2022! This contributes to our upward trajectory as we work to ensure that as cancer treatments improve, more patients benefit. CellVec is attending the 7...

CellVec attended the ASGCT 25th Annual Meeting in Washington, D.C. from 16 to 19 May 2022. We were delighted to enjoy meaningful conversations with the CGT industry, learning more about how we can create new opportunities for therapeutics together....

CellVec attended the 63rd @American Society of Hematology (ASH) Annual Meeting in Georgia, Atlanta from 11-14 December 2021. The delegates had meaningful conversations with key industry players, paving the way for scaling new heights in viral vector production for the hematology space....

CellVec attended the 6th CAR-TCR Summit happening online next week from 30 August to 2 September, which gave insight into how disruptive CAR & TCR-based cell technologies can drive immunotherapies in oncology and beyond....